美罗培南在肺、支气管黏膜及胸膜组织中的穿透性。
Penetration of meropenem in lung, bronchial mucosa, and pleural tissues.
作者信息
Byl B, Jacobs F, Roucloux I, de Franquen P, Cappello M, Thys J P
机构信息
Infectious Diseases Clinic, Erasme Hospital, Université Libre de Bruxelles, Belgium.
出版信息
Antimicrob Agents Chemother. 1999 Mar;43(3):681-2. doi: 10.1128/AAC.43.3.681.
Abstract
Lung, bronchial mucosa, and pleural tissue samples were obtained from 14 patients undergoing lung surgery 1 to 5 h after administration of 1 g of meropenem. The mean (range) peak concentrations of meropenem were 3.9 (0.2 to 8.2), 6.6 (3.0 to 13.3), and 2.8 (0.6 to 7.8) mg/kg of tissue, respectively, exceeding the MICs at which 90% of isolates are inhibited for most respiratory pathogens.
摘要
在给予1克美罗培南后1至5小时，从14例接受肺手术的患者中获取肺、支气管黏膜和胸膜组织样本。美罗培南的平均（范围）峰值浓度分别为3.9（0.2至8.2）、6.6（3.0至13.3）和2.8（0.6至7.8）毫克/千克组织，超过了对大多数呼吸道病原体90%分离株具有抑制作用的最低抑菌浓度。
相似文献
1
Penetration of meropenem in lung, bronchial mucosa, and pleural tissues.美罗培南在肺、支气管黏膜及胸膜组织中的穿透性。
Antimicrob Agents Chemother. 1999 Mar;43(3):681-2. doi: 10.1128/AAC.43.3.681.
2
The penetration of ciprofloxacin into bronchial mucosa, lung parenchyma, and pleural tissue after intravenous administration.
Eur J Clin Pharmacol. 1993;44(1):101-2. doi: 10.1007/BF00315290.
3
Concentration of meropenem in serum and in bronchial secretions in patients undergoing fibreoptic bronchoscopy.接受纤维支气管镜检查患者血清和支气管分泌物中美罗培南的浓度。
Eur J Clin Pharmacol. 1994;46(1):87-8. doi: 10.1007/BF00195922.
4
Penetration of ciprofloxacin and metabolites into human lung, bronchial and pleural tissue after 250 and 500 mg oral ciprofloxacin.口服250毫克和500毫克环丙沙星后，环丙沙星及其代谢产物在人肺、支气管和胸膜组织中的渗透情况。
Chemotherapy. 1991;37(4):229-38. doi: 10.1159/000238860.
5
Pharmacokinetics of cefonicid in serum and its penetration into lung tissue, bronchial mucosa and pleura.
Int J Clin Pharmacol Res. 1989;9(1):49-53.
6
Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis.通过体内微透析测定美罗培南在人肺炎肺组织中的渗透情况。
Antimicrob Agents Chemother. 2004 Jun;48(6):2228-32. doi: 10.1128/AAC.48.6.2228-2232.2004.
7
Respiratory tract distribution and bioavailability of spiramycin in calves.螺旋霉素在犊牛呼吸道的分布及生物利用度
Am J Vet Res. 1991 Aug;52(8):1269-73.
8
Penetration of danofloxacin into the respiratory tract tissues and secretions in calves.
Am J Vet Res. 1993 Jul;54(7):1122-7.
9
Concentrations of single-dose meropenem (1 g iv) in bronchoalveolar lavage and epithelial lining fluid.单剂量美罗培南（1克静脉注射）在支气管肺泡灌洗和上皮衬液中的浓度。
J Antimicrob Chemother. 2000 Aug;46(2):319-22. doi: 10.1093/jac/46.2.319.
10
Meropenem pharmacokinetics and penetration into an inflammatory exudate.美罗培南的药代动力学及对炎性渗出液的穿透性。
Antimicrob Agents Chemother. 1990 Aug;34(8):1515-7. doi: 10.1128/AAC.34.8.1515.
引用本文的文献
1
Target Site Pharmacokinetics of Meropenem: Measurement in Human Explanted Lung Tissue by Bronchoalveolar Lavage, Microdialysis, and Homogenized Lung Tissue.美罗培南的靶位药代动力学：支气管肺泡灌洗、微透析和肺组织匀浆在人离体肺组织中的测量。
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0156421. doi: 10.1128/AAC.01564-21. Epub 2021 Sep 27.
2
Evaluation of a New Culture-Based AtbFinder Test-System Employing a Novel Nutrient Medium for the Selection of Optimal Antibiotics for Critically Ill Patients with Polymicrobial Infections within 4 h.评估一种基于培养的新型AtbFinder检测系统，该系统采用新型营养培养基，可在4小时内为患有多重微生物感染的重症患者选择最佳抗生素。
Microorganisms. 2021 May 4;9(5):990. doi: 10.3390/microorganisms9050990.
3
Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study.急性-on-慢性肝衰竭改变了接受持续血液透析的重症患者美罗培南的药代动力学：一项观察性研究。
Ann Intensive Care. 2020 Apr 22;10(1):48. doi: 10.1186/s13613-020-00666-8.
4
Is Meropenem as a Monotherapy Truly Incompetent for Meropenem-Nonsusceptible Bacterial Strains? A Pharmacokinetic/Pharmacodynamic Modeling With Monte Carlo Simulation.美罗培南单药治疗对美罗培南不敏感的细菌菌株真的无效吗？一项基于蒙特卡洛模拟的药代动力学/药效学建模研究。
Front Microbiol. 2019 Nov 29;10:2777. doi: 10.3389/fmicb.2019.02777. eCollection 2019.
5
Plasma and Renal Cortex Meropenem Concentrations in Patients Undergoing Percutaneous Renal Biopsy.经皮肾活检患者的血浆和肾皮质美罗培南浓度。
Biomed Res Int. 2019 Nov 19;2019:1368397. doi: 10.1155/2019/1368397. eCollection 2019.
6
Filamentous bacteriophages are associated with chronic lung infections and antibiotic resistance in cystic fibrosis.丝状噬菌体与囊性纤维化患者肺部慢性感染和抗生素耐药性有关。
Sci Transl Med. 2019 Apr 17;11(488). doi: 10.1126/scitranslmed.aau9748.
7
Meropenem Dosing Based on a Population Pharmacokinetic-Pharmacodynamic Model in Elderly Patients with Infection of the Lower Respiratory Tract.基于群体药代动力学-药效学模型的美罗培南在老年下呼吸道感染患者中的给药方案
Drugs Aging. 2017 Feb;34(2):115-121. doi: 10.1007/s40266-016-0431-9.
8
In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest.采用肉汤微量稀释法和Etest法对厄他培南、美罗培南和亚胺培南针对快速生长分枝杆菌和诺卡菌分离株进行体外比较
J Clin Microbiol. 2016 Jun;54(6):1586-1592. doi: 10.1128/JCM.00298-16. Epub 2016 Apr 6.
9
[Tissue penetration of antibiotics. Does the treatment reach the target site?].[抗生素的组织穿透性。治疗是否能到达靶部位？]
Med Klin Intensivmed Notfmed. 2014 Apr;109(3):175-81. doi: 10.1007/s00063-013-0309-0. Epub 2014 Apr 2.
10
Lung microdialysis--a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review).肺微透析——一种用于测定下呼吸道中外源性和内源性化合物的强大工具（综述）
AAPS J. 2005 Oct 22;7(3):E600-8. doi: 10.1208/aapsj070362.
本文引用的文献
1
A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min.美罗培南在5分钟静脉注射给药和30分钟静脉输注给药后的药代动力学比较。
J Antimicrob Chemother. 1995 Jul;36 Suppl A:35-41. doi: 10.1093/jac/36.suppl_a.35.
2
Meropenem: a microbiological overview.美罗培南：微生物学概述。
J Antimicrob Chemother. 1995 Jul;36 Suppl A:1-17. doi: 10.1093/jac/36.suppl_a.1.
3
Correlation between macrolide lung pharmacokinetics and therapeutic efficacy in a mouse model of pneumococcal pneumonia.肺炎球菌肺炎小鼠模型中大环内酯类药物肺部药代动力学与治疗效果的相关性
J Antimicrob Chemother. 1993 Sep;32(3):473-82. doi: 10.1093/jac/32.3.473.
4
Predicting the efficacy of antimicrobial agents in respiratory infections--is tissue concentration a valid measure?预测抗菌药物在呼吸道感染中的疗效——组织浓度是一项有效的衡量指标吗？
J Antimicrob Chemother. 1995 Mar;35(3):363-71. doi: 10.1093/jac/35.3.363.
5
The pharmacokinetics of meropenem.美罗培南的药代动力学。
Scand J Infect Dis Suppl. 1995;96:11-6.
6
Therapeutic efficacy of cefadroxil and cephalexin for pneumonia in a rat test model.头孢羟氨苄和头孢氨苄在大鼠肺炎试验模型中的治疗效果。
Antimicrob Agents Chemother. 1986 Jul;30(1):105-9. doi: 10.1128/AAC.30.1.105.
7
Imipenem kinetics in serum, lung tissue and pericardial fluid in patients undergoing thoracotomy.开胸手术患者血清、肺组织和心包液中亚胺培南的动力学
J Antimicrob Chemother. 1987 Nov;20(5):725-8. doi: 10.1093/jac/20.5.725.
8
Azithromycin (CP-62,993) in acute exacerbations of chronic bronchitis: an open clinical, microbiological and pharmacokinetic study.阿奇霉素（CP-62,993）用于慢性支气管炎急性加重期：一项开放性临床、微生物学及药代动力学研究。
J Antimicrob Chemother. 1989 May;23(5):743-51. doi: 10.1093/jac/23.5.743.
9
Meropenem pharmacokinetics and penetration into an inflammatory exudate.美罗培南的药代动力学及对炎性渗出液的穿透性。
Antimicrob Agents Chemother. 1990 Aug;34(8):1515-7. doi: 10.1128/AAC.34.8.1515.
10
Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.环丙沙星、氧氟沙星和替马沙星在实验性小鼠肺炎模型疾病不同阶段的抗肺炎球菌活性。
J Infect Dis. 1991 Feb;163(2):319-24. doi: 10.1093/infdis/163.2.319.
Zotero 插件